153 related articles for article (PubMed ID: 32250189)
1. Repolarization of glioblastoma macrophage cells using non-agonistic Dectin-1 ligand encapsulating TLR-9 agonist: plausible role in regenerative medicine against brain tumor.
Tiwari RK; Singh S; Gupta CL; Pandey P; Singh VK; Sayyed U; Shekh R; Bajpai P
Int J Neurosci; 2021 Jun; 131(6):591-598. PubMed ID: 32250189
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of SPG-ODN 1826 Nanovehicles in Inducing M1 Phenotype through TLR-9 Activation in Murine Alveolar J774A.1 Cells: Plausible Nano-Immunotherapy for Lung Carcinoma.
Aldawsari MF; Alalaiwe A; Khafagy ES; Al Saqr A; Alshahrani SM; Alsulays BB; Alshehri S; Abu Lila AS; Danish Rizvi SM; Hegazy WAH
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202080
[TBL] [Abstract][Full Text] [Related]
3. Leishmanial CpG DNA nanovesicles: A propitious prophylactic approach against visceral leishmaniasis.
Tiwari RK; Chandrakar P; Gupta CL; Sayyed U; Shekh R; Bajpai P
Int Immunopharmacol; 2021 Jan; 90():107181. PubMed ID: 33249044
[TBL] [Abstract][Full Text] [Related]
4. Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist.
Kobiyama K; Aoshi T; Narita H; Kuroda E; Hayashi M; Tetsutani K; Koyama S; Mochizuki S; Sakurai K; Katakai Y; Yasutomi Y; Saijo S; Iwakura Y; Akira S; Coban C; Ishii KJ
Proc Natl Acad Sci U S A; 2014 Feb; 111(8):3086-91. PubMed ID: 24516163
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Therapeutic Efficacy of Immunostimulatory CpG-ODN by Silencing SOCS-1 with Polysaccharide/miR-155 Complexes.
Sumiya K; Izumi H; Sakurai K
ACS Appl Bio Mater; 2023 Feb; 6(2):774-783. PubMed ID: 36632777
[TBL] [Abstract][Full Text] [Related]
6. Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells.
Kitahata Y; Kanuma T; Hayashi M; Kobayashi N; Ozasa K; Kusakabe T; Temizoz B; Kuroda E; Yamaue H; Coban C; Yamamoto T; Kobiyama K; Aoshi T; Ishii KJ
Oncotarget; 2016 Aug; 7(31):48860-48869. PubMed ID: 27384490
[TBL] [Abstract][Full Text] [Related]
7. Designing an immunocyte-targeting delivery system by use of beta-glucan.
Miyamoto N; Mochizuki S; Sakurai K
Vaccine; 2018 Jan; 36(1):186-189. PubMed ID: 29174675
[TBL] [Abstract][Full Text] [Related]
8. Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study.
Ursu R; Carpentier A; Metellus P; Lubrano V; Laigle-Donadey F; Capelle L; Guyotat J; Langlois O; Bauchet L; Desseaux K; Tibi A; Chinot O; Lambert J; Carpentier AF
Eur J Cancer; 2017 Mar; 73():30-37. PubMed ID: 28142059
[TBL] [Abstract][Full Text] [Related]
9. Synergistic stimulation of antigen presenting cells via TLR by combining CpG ODN and poly(γ-glutamic acid)-based nanoparticles as vaccine adjuvants.
Shima F; Uto T; Akagi T; Akashi M
Bioconjug Chem; 2013 Jun; 24(6):926-33. PubMed ID: 23631730
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Innate Responses Induced by PLGA Encapsulated- and Soluble TLR Ligands In Vitro and In Vivo in Chickens.
Alkie TN; Taha-Abdelaziz K; Barjesteh N; Bavananthasivam J; Hodgins DC; Sharif S
PLoS One; 2017; 12(1):e0169154. PubMed ID: 28045984
[TBL] [Abstract][Full Text] [Related]
11. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
Mochizuki S; Morishita H; Kobiyama K; Aoshi T; Ishii KJ; Sakurai K
J Control Release; 2015 Dec; 220(Pt A):495-502. PubMed ID: 26562685
[TBL] [Abstract][Full Text] [Related]
12. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
Roda JM; Parihar R; Carson WE
J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
[TBL] [Abstract][Full Text] [Related]
13. Species-dependent role of type I IFNs and IL-12 in the CTL response induced by humanized CpG complexed with β-glucan.
Kobiyama K; Temizoz B; Kanuma T; Ozasa K; Momota M; Yamamoto T; Aoshi T; Kuroda E; Ishii KJ
Eur J Immunol; 2016 May; 46(5):1142-51. PubMed ID: 26786557
[TBL] [Abstract][Full Text] [Related]
14. Phosphorothioate modification of the TLR9 ligand CpG ODN inhibits poly(I:C)-induced apoptosis of hepatocellular carcinoma by entry blockade.
Zhang Y; Lin A; Sui Q; Zhang C; Tian Z; Zhang J
Cancer Lett; 2014 Dec; 355(1):76-84. PubMed ID: 25224571
[TBL] [Abstract][Full Text] [Related]
15. Induction of a balanced Th1/Th2 immune responses by co-delivery of PLGA/ovalbumin nanospheres and CpG ODNs/PEI-SWCNT nanoparticles as TLR9 agonist in BALB/c mice.
Ebrahimian M; Hashemi M; Maleki M; Abnous K; Hashemitabar G; Ramezani M; Haghparast A
Int J Pharm; 2016 Dec; 515(1-2):708-720. PubMed ID: 27989827
[TBL] [Abstract][Full Text] [Related]
16. Induction of humoral and cellular immune response to hepatitis B virus (HBV) vaccine can be upregulated by CpG oligonucleotides complexed with Dectin-1 ligand.
Ito H; Ando T; Nakamura M; Ishida H; Kanbe A; Kobiyama K; Yamamoto T; Ishii KJ; Hara A; Seishima M; Ishikawa T
J Viral Hepat; 2017 Feb; 24(2):155-162. PubMed ID: 27807909
[TBL] [Abstract][Full Text] [Related]
17. [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].
Ren T; Cai YY; Liang YJ; Jin ML; Guo ZL; Tao MF; He X
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1168-72. PubMed ID: 18844109
[TBL] [Abstract][Full Text] [Related]
18. Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif.
Zhang Y; Shoda LK; Brayton KA; Estes DM; Palmer GH; Brown WC
J Interferon Cytokine Res; 2001 Oct; 21(10):871-81. PubMed ID: 11711000
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor 9 and 21 have different ligand recognition profiles and cooperatively mediate activity of CpG-oligodeoxynucleotides in zebrafish.
Yeh DW; Liu YL; Lo YC; Yuh CH; Yu GY; Lo JF; Luo Y; Xiang R; Chuang TH
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20711-6. PubMed ID: 24282308
[TBL] [Abstract][Full Text] [Related]
20. Microglial TLR9: Plausible Novel Target for Therapeutic Regime Against Glioblastoma Multiforme.
Tiwari RK; Singh S; Gupta CL; Bajpai P
Cell Mol Neurobiol; 2021 Oct; 41(7):1391-1393. PubMed ID: 32691190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
